Veru Announces Publication Of Data From Three Cancer Studies As Part Of The Upcoming American Society Of Clinical Oncology Annual Meeting | Latest News RSS feed

Veru Announces Publication Of Data From Three Cancer Studies As Part Of The Upcoming American Society Of Clinical Oncology Annual Meeting - Latest News


Veru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting

May 17, 2018 08:30 ET | Source: Veru Inc. MIAMI, May 17, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced the publication of data fro... read more

Veru Reports Fiscal 2018 Third Quarter Financial Results

MIAMI, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... triple negative breast cancer, as well as ovarian cancer and pancreatic cancer) were presented as part of the American Society of Clinica... read more

TESARO Announces Third-Quarter 2018 Operating Results

Nov. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (TSRO), an oncology ... data from the Phase 1 AMBER trial of our anti-TIM-3 antibody, TSR-022, in combination with TSR-042, which will be presented at th... read more

Looking for another news?


AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types

AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts ... oncology medicines during the 52 nd Annual Meeting of the American Society of Clinical ... pre... read more


Agios Reports Fourth Quarter and Full Year 2017 Financial Results

Presented new and updated data from the IDH and PKR programs at the 2017 American Society of Hematology Annual Meeting and ... has an approved oncology precision medicine and multiple first-in-class i... read more

Curis, Inc. (CRIS)

On November 7, 2017, Curis, Inc. announced its financial results for the three ... Cancer (SITC) Meeting. In our CUDC-907 program, we expect to present data supporting its clinical benefit in patients ... read more

Quoth Joe Mercola: I love me some Burzynski antineoplastons

In short, personalized cancer treatment is the future of oncology ... phase I toxicity studies, and some phase II clinical studies examining the effectiveness of antineoplaston therapy have been publi... read more

Final Results

Verseon (AIM:VSN), a technology-based pharmaceutical company, today announces its Final Results and the publication of its Annual ... At the 2016 American Society of Hematology Annual Meeting, we pres... read more

Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates

Three notable publications provided particularly meaningful clinical insight into single-agent ibrutinib. In addition to the aforementioned publication by Levy ... at the AACR Meeting featured a data ... read more

Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Expanded three-month ... with pancreatic cancer, and is further exploring additional studies in other cancers. Preclinical Work Continues in Gene Therapy: Previously presented data from the 2017 annua... read more

Chi-Med Announces Proposed Offering of ADSs

London: Tuesday, October 24, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of ... read more

Biocartis Group NV: Biocartis announces H1 2016 results

the Idylla(TM) KRAS Mutation Test, and their relevance in clinical practice, at the upcoming ESMO meeting in October ... resistance in colorectal cancer. Nat Med 2012; 18: 221-223. [4] American Societ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us